Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


LUX biotechnology announces appointment of Chief Operating Officer

LUX biotechnology limited (LUX), a specialist developer of light based detection technologies, announced today the appointment of Mr Bryan Smith as Chief Operating Officer of the Company.

Bryan Smith joins the management team following over 12 years experience in operations and operational consulting. Mr Smith joins LUX from PricewaterhouseCoopers where his role as Management Consultant, included the delivery of operations and supply chain reviews to verify compliance with appropriate standards (including ISO and FDA) and identify opportunities for cost and service improvement. Mr. Smith previously worked as a LeanSigma Expert for GlaxoSmithKline within their Global Manufacturing and Supply organisation, where he identified and managed step change projects delivering significantly lower operational costs and increased efficiency. Prior to this, Mr. Smith had extensive experience in production management at SmithKline Beecham. On joining LUX, Mr. Smith will manage all operations at LUX and will work to maximise the performance of its processes.

LUX’s core competencies lie in the rapid development and commercialization of technology with carefully selected partners. The Edinburgh based biotech company has seen rapid growth in the last 12 months along with demand for its solutions from diverse sectors including energy, chemical, water quality, medical and life science industries.

Dr Artin Moussavi, the CEO stated: “We are delighted that Bryan has agreed to join LUX biotechnology’s management team. His experience and proven skills in managing operational change, quality and effectiveness is an extremely valuable addition to the team and will help us to excel on a number of projects which will reach market in the next 18 months. As LUX continues to grow, Bryan will be well placed to lead the company’s operations as we prepare to expand into the next phase of our development.”

Bryan Smith stated: “I am very pleased to be joining LUX at this exciting stage in their development. I believe that LUX has the management team and the technology to succeed and become a leading organisation in the world renowned Scottish biotechnology cluster.”


Bryan Smith joined PricewaterhouseCoopers LLP in 2004 as a client facing Manager in their Operational Effectiveness Consultancy Team with responsibility for the delivery of operational improvement engagements across both private and public sector organisations including advising on the strategic impacts of supply chain developments; the delivery of vendor and buy-side operational due diligence including reviews against ISO 9001 and 13485 standards and business development.

Prior to joining PwC, Mr. Smith worked at both SmithKline Beecham and then GlaxoSmithKline. He held a number of positions including Operations Team Leader and LeanSigma Expert. In his capacity as LeanSigma Expert, he was responsible for project and change management and the training and mentorship of staff in the application of Lean and Six Sigma techniques. He identified and managed projects to improve business performance through increased operational efficiency and improved product quality. Mr. Smith holds a bachelor's degree in Chemistry and Biology from the University of Aston; a post graduate diploma in Industrial Pharmaceutical Studies from the University of Brighton and an MBA from the University of Edinburgh Management School.

About LUX biotechnology ltd
LUX biotechnology Ltd. is a specialist developer of detection technologies based on light. With a track record of working with major industry players and a strong, comprehensive in-house research team the company is geared towards efficient co-development of novel light based technological solutions to unmet needs in several industrial sectors. The company has ongoing co-development projects in the energy, chemical, water and life science sectors with potential application development in many more.

A number of light<

Publisher Contact Information:

LUX Biotechnology Ltd.
+44 (0) 131 662 3350
vm @

Company profile of LUX Innovate Ltd.
Past press releases of LUX Innovate Ltd..


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Feb 14€19.0MBiopharmaceuticals
Feb 14N/AInternet services
Feb 14€4.6MBusiness applications
Feb 13€13.0MBiopharmaceuticals
Feb 13€25.0MMedical devices
Feb 13€15.0MBusiness applications

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.